Literature DB >> 9458088

A lack of neuroblastoma in Down syndrome: a study from 11 European countries.

D Satgé1, A J Sasco, N L Carlsen, C A Stiller, H Rubie, B Hero, B de Bernardi, J de Kraker, C Coze, P Kogner, F Langmark, F G Hakvoort-Cammel, D Beck, N von der Weid, S Parkes, O Hartmann, R J Lippens, W A Kamps, D Sommelet.   

Abstract

An epidemiological investigation in 11 European countries comprising a total childhood population of 54.1 million children and using 8 separate data sources was conducted to evaluate the occurrence of neuroblastoma in Down syndrome (DS). No cases of DS were detected among 6724 infants and children with neuroblastoma, although more than five were expected. This highly significant result (P = 0.0045 according to the Poisson test) is consistent with data in the literature, which contains only two poorly detailed cases in epidemiological studies and one ganglioneuroma in a DS mosaic patient. Like other tumors, such as leukemias, testicular germ cell tumors and lymphomas are in excess in DS patients; the lack of neuroblastomas does not reflect a general decreased incidence of cancer but rather a specific underrepresentation of this precise tumor. S-100 b protein, the gene for which maps to the long arm of chromosome 21, (a) is overproduced in DS patients, (b) produces growth inhibition and differentiation of neural cells in vitro, (c) is abundant in good-prognosis neuroblastomas, and (d) has been shown to induce growth inhibition and differentiation and cell death in several human and murine neuroblastoma cell lines and could be responsible for this variation. Additional epidemiological and experimental studies are warranted to confirm our interpretation of these data.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9458088

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Reduced levels of DEAD-box proteins DBP-RB and p72 in fetal Down syndrome brains.

Authors:  Susanne G Kircher; Seong Hwan Kim; Michael Fountoulakis; Gert Lubec
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

2.  Survival and morbidity outcomes for very low birth weight infants with Down syndrome.

Authors:  Nansi S Boghossian; Nellie I Hansen; Edward F Bell; Barbara J Stoll; Jeffrey C Murray; Abbot R Laptook; Seetha Shankaran; Michele C Walsh; Abhik Das; Rosemary D Higgins
Journal:  Pediatrics       Date:  2010-11-22       Impact factor: 7.124

3.  Tongue carcinoma in an adult Down's syndrome patient: a case report.

Authors:  Fadi S Farhat; Fady Geara; Mohamed Natout; Jamal Serhal; Walid Daya
Journal:  World J Surg Oncol       Date:  2009-03-04       Impact factor: 2.754

Review 4.  Neonatal tumours.

Authors:  S W Moore
Journal:  Pediatr Surg Int       Date:  2013-10-31       Impact factor: 1.827

5.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome.

Authors:  Dean Nižetić; Jürgen Groet
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

6.  Germline 16p11.2 Microdeletion Predisposes to Neuroblastoma.

Authors:  Laura E Egolf; Zalman Vaksman; Gonzalo Lopez; Jo Lynne Rokita; Apexa Modi; Patricia V Basta; Hakon Hakonarson; Andrew F Olshan; Sharon J Diskin
Journal:  Am J Hum Genet       Date:  2019-08-29       Impact factor: 11.025

Review 7.  Constitutional aneuploidy and cancer predisposition.

Authors:  Ithamar Ganmore; Gil Smooha; Shai Izraeli
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

Review 8.  SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature.

Authors:  Ross Mangum; Elizabeth Varga; Daniel R Boué; David Capper; Martin Benesch; Jeffrey Leonard; Diana S Osorio; Christopher R Pierson; Nicholas Zumberge; Felix Sahm; Daniel Schrimpf; Stefan M Pfister; Jonathan L Finlay
Journal:  Childs Nerv Syst       Date:  2016-07-21       Impact factor: 1.475

Review 9.  Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.

Authors:  Ana C Xavier; Yubin Ge; Jeffrey W Taub
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568

10.  Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.

Authors:  Kwan-Hyuck Baek; Alexander Zaslavsky; Ryan C Lynch; Carmella Britt; Yoshiaki Okada; Richard J Siarey; M William Lensch; In-Hyun Park; Sam S Yoon; Takashi Minami; Julie R Korenberg; Judah Folkman; George Q Daley; William C Aird; Zygmunt Galdzicki; Sandra Ryeom
Journal:  Nature       Date:  2009-05-20       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.